Drug profile · INN
rilonacept
RILONACEPT FGK REPRESENTATIVE SERVICE GMBH
rilonacept (RILONACEPT FGK REPRESENTATIVE SERVICE GMBH) is a interleukin-1 beta inhibitor. Associated with Regeneron UK Limited. Route of administration: single-use. Current US regulatory status: approved.
Drug details — rilonacept
- US status
- approved
- Class
- Antineoplastic and immunomodulating agents (L04)
- Route
- SINGLE-USE
- Patents
- 0
- Programs
- 10
- Data quality
- 0.89
Quick answer
rilonacept (RILONACEPT FGK REPRESENTATIVE SERVICE GMBH) is a interleukin-1 beta inhibitor. Associated with Regeneron UK Limited. Route of administration: single-use. Current US regulatory status: approved.
Key facts
Mechanism of action
Interleukin-1 beta inhibitor
Primary target: Interleukin-1 beta
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | application withdrawn | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is rilonacept?
rilonacept (RILONACEPT FGK REPRESENTATIVE SERVICE GMBH) is a interleukin-1 beta inhibitor. Associated with Regeneron UK Limited. Route of administration: single-use. Current US regulatory status: approved.
What is the brand name for rilonacept?
RILONACEPT FGK REPRESENTATIVE SERVICE GMBH is a marketed brand name for rilonacept. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of rilonacept?
rilonacept has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.